Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sapio Sciences Announces Exemplar LIMS for Clinical and Research NGS Labs

Published: Tuesday, February 25, 2014
Last Updated: Tuesday, February 25, 2014
Bookmark and Share
Purpose-built system handles the sample tracking and processing needs of clinical or research laboratories

Sapio Sciences has announced Exemplar LIMS for clinical and research NGS labs.   Exemplar NGS LIMS is a system built to handle the sample tracking and processing needs of clinical or research laboratories. Exemplar provides complete tracking of samples through the NGS pipeline from request through sample processing and results delivery. It provides automation integration as needed, along with preconfigured workflows, management level dashboards, full consumables management and support for regulatory compliance such as CLIA.

The dynamic nature of the NGS lab requires a LIMS that can adapt quickly to changing protocols and platforms. Exemplar is the most configurable LIMS at all levels, meaning that no matter what technology you introduce into your lab or what your requirements are, you can be confident that Exemplar can meet your needs.

When evaluating a LIMS, labs should choose a system that:

Is fully web based for complete end user usage and configuration and is usable on tablet computers.
Tracks volumes of samples through the pipeline
Has pre-built, CLIA standard, NGS workflows
Fully tracks aliquot and derivative lineage
Tracks samples and workflows throughout the pipeline.
Collects quality control data and integrates with all leading QC genomics instruments.
Can fully track consumables including amount remaining in inventory and expiration dates.
Is highly configurable to easily alter existing workflows and when creating new ones.
Includes graphical dashboards of lab activity
Is highly scalable to handle anticipated concurrent users and sample volumes for many years
Can support any additional lab process outside the NGS arena
This extent of this list is daunting for a new MDx company to consider as a thorough implementation of these features could require 4 or more software solutions and years of work. New labs also need to get CLIA certification and may also need to operate under GLP and/or be a validated lab per FDA Part 11 specifications.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!